SynCore Biotechnology Co.,Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 10, 2022
Share
SynCore Biotechnology Co.,Ltd reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was TWD 4.48 million compared to TWD 1.48 million a year ago. Net loss was TWD 30.59 million compared to TWD 218.65 million a year ago. Basic loss per share from continuing operations was TWD 1.0106 compared to TWD 7.1117 a year ago.
For the nine months, sales was TWD 10.76 million compared to TWD 4.07 million a year ago. Net loss was TWD 106.93 million compared to TWD 378.46 million a year ago. Basic loss per share from continuing operations was TWD 3.481 compared to TWD 12.5017 a year ago.
SynCore Biotechnology Co.,Ltd is a Taiwan-based company principally engaged in the research, development, production and sales of therapeutic drugs. The Company's main product is SB03 Veregen. The Company is also involved in research, development and clinical trials of the injection-type anticancer drug, SB01 and the oral anticancer drug, SB01. The Company distributes its products mainly in domestic market.